Therefore, we aimed to characterize if the expression levels of FOXO1 and SIRT1 in PBMCs in postmenopausal women with overweight/obesity are associated with MASLD risk biomarkers/indicators, and whether they can be modulated by DHA-rich n-3 PUFA supplementation and/or resistance training. This evidence concerns the gene FOXO1 and obesity disorder.